Cargando…

Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial

Background: Although there is a growing number of early childhood obesity prevention programs, only a few of them are effective in the long run. Even fewer reports exist on lifetime cost-effectiveness of early prevention strategies. This paper aimed to assess the lifetime cost-effectiveness of infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonntag, Diana, De Bock, Freia, Totzauer, Martina, Koletzko, Berthold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682975/
https://www.ncbi.nlm.nih.gov/pubmed/31331027
http://dx.doi.org/10.3390/nu11071653
_version_ 1783441989042176000
author Sonntag, Diana
De Bock, Freia
Totzauer, Martina
Koletzko, Berthold
author_facet Sonntag, Diana
De Bock, Freia
Totzauer, Martina
Koletzko, Berthold
author_sort Sonntag, Diana
collection PubMed
description Background: Although there is a growing number of early childhood obesity prevention programs, only a few of them are effective in the long run. Even fewer reports exist on lifetime cost-effectiveness of early prevention strategies. This paper aimed to assess the lifetime cost-effectiveness of infant feeding modification aiming at reducing risk of later obesity. Methods: The simulation model consists of two parts: (a) Model I used data from the European Childhood Obesity Project (CHOP) trial (up to 6 years) and the German Interview and Examination Survey for Children (KiGGS) (6–17 years) to evaluate BMI trajectories of infants receiving either lower protein (LP) or higher protein (HP) content formula; and (b) Model II estimated lifetime cost-effectiveness based on Model I BMI trajectories. Compared to HP formula, LP formula feeding would incur lower costs that are attributable to childhood obesity across all decades of life. Results: Our analysis showed that LP formula would be cost-effective in terms of a positive net monetary benefit (discounted 3%) as an obesity prevention strategy. For the 19% of infants fed with formula in Germany, the LP strategy would result in cost savings of € 2.5 billion. Conclusions: Our study is one of the first efforts to provide much-needed cost-effectiveness evidence of infant feeding modification, thereby potentially motivating interventionists to reassess their resource allocation.
format Online
Article
Text
id pubmed-6682975
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66829752019-08-09 Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial Sonntag, Diana De Bock, Freia Totzauer, Martina Koletzko, Berthold Nutrients Article Background: Although there is a growing number of early childhood obesity prevention programs, only a few of them are effective in the long run. Even fewer reports exist on lifetime cost-effectiveness of early prevention strategies. This paper aimed to assess the lifetime cost-effectiveness of infant feeding modification aiming at reducing risk of later obesity. Methods: The simulation model consists of two parts: (a) Model I used data from the European Childhood Obesity Project (CHOP) trial (up to 6 years) and the German Interview and Examination Survey for Children (KiGGS) (6–17 years) to evaluate BMI trajectories of infants receiving either lower protein (LP) or higher protein (HP) content formula; and (b) Model II estimated lifetime cost-effectiveness based on Model I BMI trajectories. Compared to HP formula, LP formula feeding would incur lower costs that are attributable to childhood obesity across all decades of life. Results: Our analysis showed that LP formula would be cost-effective in terms of a positive net monetary benefit (discounted 3%) as an obesity prevention strategy. For the 19% of infants fed with formula in Germany, the LP strategy would result in cost savings of € 2.5 billion. Conclusions: Our study is one of the first efforts to provide much-needed cost-effectiveness evidence of infant feeding modification, thereby potentially motivating interventionists to reassess their resource allocation. MDPI 2019-07-19 /pmc/articles/PMC6682975/ /pubmed/31331027 http://dx.doi.org/10.3390/nu11071653 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sonntag, Diana
De Bock, Freia
Totzauer, Martina
Koletzko, Berthold
Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title_full Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title_fullStr Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title_full_unstemmed Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title_short Assessing the Lifetime Cost-Effectiveness of Low-Protein Infant Formula as Early Obesity Prevention Strategy: The CHOP Randomized Trial
title_sort assessing the lifetime cost-effectiveness of low-protein infant formula as early obesity prevention strategy: the chop randomized trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682975/
https://www.ncbi.nlm.nih.gov/pubmed/31331027
http://dx.doi.org/10.3390/nu11071653
work_keys_str_mv AT sonntagdiana assessingthelifetimecosteffectivenessoflowproteininfantformulaasearlyobesitypreventionstrategythechoprandomizedtrial
AT debockfreia assessingthelifetimecosteffectivenessoflowproteininfantformulaasearlyobesitypreventionstrategythechoprandomizedtrial
AT totzauermartina assessingthelifetimecosteffectivenessoflowproteininfantformulaasearlyobesitypreventionstrategythechoprandomizedtrial
AT koletzkoberthold assessingthelifetimecosteffectivenessoflowproteininfantformulaasearlyobesitypreventionstrategythechoprandomizedtrial